ドプテレット®錠20mg

＜アバトロンボパグマレイン酸塩＞

（慢性特発性血小板減少性紫斑病）

第 2 部（モジュール 2）
CTD の概要（サマリー）
2.7　臨床概要
2.7.5 参考文献

Swedish Orphan Biovitrum Japan 株式会社

Property of the SOBI group - strictly confidential

目次

2.7.5 参考文献.....3

2.7.5 参考文献

Al-Samkari H, Kuter, DJ. An alternative intermittent eltrombopag dosing protocol for treatment of chronic immune thrombocytopenia. Br J Clin Pharmacol. 2018; 84(11): 2673-2677.

Bussel JB, Cheng G, Saleh MN, Psaila B, Kovaleva L, Meddeb B, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med. 2007; 357: 2237-2247.

Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med. 2002; 346(13): 995-1008.

Frederiksen H, Schmidt K. The incidence of idiopathic thrombocytopenic purpura in adults increases with age. Blood. 1999; 94: 909-913.

Gernsheimer T. Epidemiology and pathophysiology of immune thrombocytopenic purpura. Eur J Haematol. 2008; 80(s69): 3-8.

Imbach P, Crowther M. Thrombopoietin-Receptor Agonists for Primary Immune Thrombocytopenia. N Engl J Med. 2011; 365: 734-741.

Jenkins JM, Williams D, Deng Y, Uhl J, Kitchen V, Collins D, et al. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood. 2007; 109: 4739-4741.

Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet. 2008; 371: 395-403.

Kuter DJ, Rummel M, Boccia R, Macik BG, Pabinger I, Selleslag D, et al. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med. 2010; 363: 1889-1899.

Lambert MP, Gernshiemer TP. Clinical Updates in Adult Immune Thrombocytopenia (ITP). Blood. 2017; 129(21): 2829-2835.

Louwes H, Lathori OAZ, Vellenga E, de Wolf JTM. Platelet Kinetic Studies in Patients with Idiopathic Thrombocytopenic Purpura. The American Journal of Medicine. 1999; 106:430-434.

Michel M. Immune thrombocytopenia purpura: epidemiology and implications for patients. Eur J Haematol. 2009: 82 (Supp 71): 3-7.

Michel M, Rauzy OB, Thoraval FR, Languille L, Khellaf M, Bierling P, et al. Characteristics and outcome of immune thrombocytopenia in elderly: results from a single center case-controlled study. Am J Hematol. 2011; 86: 980-984.

Moustafa I, Badawy MEA, Fetouh SM. Eltrombopag-Induced Myelofibrosis in Patients with Adult Immune Thrombocytopenia: Scoping Review. EMJ Hematol. 2019; 7(1): 69-79.

Perera M, Garrido T. Advances in the pathophysiology of primary immune thrombocytopenia. Hematology. 2017; 22(1): 41-53.

Provan D, Arnold DM, Bussel JB, Chong BH, Cooper N, Gernsheimer T, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019; 3(22): 3780-3817.

Stasi R. Pathophysiology and therapeutic options in primary immune thrombocytopenia. Blood Transfus. 2011; 9(3): 262-273.

Wong RSM, Saleh MN, Khelif A, Salama A, Portella MSO, Burgess P, et al. Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study. Blood. 2017; 130(23): 2527-2536.

Zufferey A, Kapur R, Semple JW. Pathogenesis and Therapeutic Mechanisms in Immune Thrombocytopenia (ITP). J. Clin. Med. 2017; 6(2): 16.

成人特発性血小板減少性紫斑病治療の参照ガイド 2019 改訂版
厚生労働省難治性疾患政策研究事業　血液凝固異常症等に関する研究班
「ITP 治療の参照ガイド」作成委員会